Similar results were reported in a study using single-center data from the United States, in which the median OS from the date of diagnosis of metastatic disease in patients with KRAS-mutant lung adenocarcinomas was 13 months in de novo patients and 18 months in recurrent patients (HR, 1.41) [9]. Here, KRAS is linked to lung adenocarcinoma.